AbbVie Inc. continues racking up indications for its JAK1 inhibitor, Rinvoq (upadacitinib), winning its fourth indication since the US Food and Drug Administration cleared it for rheumatoid arthritis in 2019. The drug moved into the gastrointestinal space on 16 March with a supplemental approval for ulcerative colitis, which followed FDA nods in December and January for psoriatic arthritis and atopic dermatitis, respectively.
AbbVie has talked up Rinvoq’s potential efficacy in inflammatory bowel disease (IBD) during recent investor presentations, with president Michael Severino...






